ABSTRACT. Acute and residual effects of blood-brain barrier disruption and bilirubin on brain metabolism were studied in a rat model after osmotic opening of the bloodbrain barrier under pentobarbital anesthesia. Arabinose (1.5 M) was infused via the right external carotid artery over 30 s, resulting in opening of the barrier within the right hemisphere. Two min later, bilirubin was infused i.v. over 3 min, raising the serum bilirubin concentration to 37-44 mg/dL (633-752 pmol/L). The animals were euthanized at 15 min or 4 h by freezing the brain in situ.
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Opening the blood-brain barrier produced small changes in cerebral energy metabolism in some animals a t 15 min. Compared with saline-infused control animals, two out of nine rats had decreased brain phosphocreatine and three out of nine developed increased brain lactate levels. Infusion of bilirubin in rats with a disrupted blood-brain barrier produced profound decreases in brain energy metabolites, glucose, and glycogen and a markedly increased lactate/ pyruvate ratio a t 15 min. The markedly increased lactate in the presence of normal or low pyruvate in bilirubintreated animals indicates accumulation of NADH and probably reflects severe mitochondrial dysfunction. Four h after the arabinose/bilirubin infusions, the barrier would be expected to be repaired and bilirubin levels were negligible, but two out of five arabinose and three out of six bilirubin rats continued to have severely altered brain metabolism indicating residual brain injury in some animals. (Pediatr Res 30: 473-478, 1991) Abbreviations PCr, phosphocreatine BP, blood pressure
The pathogenesis of irreversible bilirubin toxicity has not been established. In vitro, bilirubin uncouples oxidative phosphorylation and, at higher concentrations, inhibits respiration in isolated brain and liver mitochondria (1-5), various tissue homogenates (6) (7) (8) (9) , and cell culture (1 0-12). Neuronal mitochondrial abnormalities, including intramitochondrial glycogen-containing vacuoles, have been observed in congenitally jaundiced homozygous ('jj) Gunn rats as early as 2 d of age (1 3-1 5). On the other hand, several investigations have failed to demonstrate changes in Rece~ved March 12, 1991 A number of factors may contribute to this confusing picture of bilirubin toxicity. Kernicterus involves specific neurons and nuclei, so that differential effects may be seen in adjacent areas and abnormalities may not be detected using large tissue samples, e.g. Diamond and Schmid (16) . McCandless and Abel (20) induced severe ataxia in Gunn rats by infusing a bilirubinalbumin binding competitor and measured metabolites in dissected freeze-dried sections of cerebella. ATP and PCr were decreased in Purkinje cell rich layers but not in molecular or granular layers, whereas glycogen and glucose were increased in all three layers. Furthermore, the metabolic response of a cell to bilirubin may vary with dose and duration of exposure. Metabolic changes may be secondary to cellular adjustments to sublethal bilirubin toxicity or reflect direct inhibition of metabolic pathways.
This study was designed to examine I ) whether bilirubin can rapidly and, by implication, directly affect brain energy metabolism in vivo, and 2 ) whether induced metabolic changes are sustained after the bilirubin exposure is withdrawn. Hyperbilirubinemia was induced by i.v. infusion of bilirubin after osmotic opening of the blood-brain barrier. By opening the blood-brain banier, the model facilitated rapid equilibration of bilirubin between serum and brain binding and circumvented to a large extent the problems of sampling, inasmuch as a large cell population was exposed to bilirubin. Under these conditions, we found evidence of severe bilirubin-induced mitochondrial dysfunction.
MATERIALS A N D METHODS
Experimental design a n d rationale. Anesthetized SpragueDawley rats were divided into three groups: arabinose controls (14 animals) received a 30-s intracarotid infusion 1. at either 15 min (10 min after completing the bilirubin infusion) to determine acute changes in brain metabolism, or 4 h later to evaluate longer term metabolic consequences of opening the blood-brain barrier and exposure to bilirubin.
The animal preparation was a modification of that described by Rapoport et a/. (21, 22) , who reported that intracarotid infusion of 1.6 M arabinose at a rate of 0.12 mL.s-' for 30 s opened the ipsilateral blood-brain barrier of rats in approximately two thirds of the animals. In our experiment, we reduced the infusion rate to 0.043 mL.s-' for 30 s because we ligated the pterygomandibular artery, a major branch of the carotid artery in rats. In a pilot study (23) , we observed that infusing 1.9 M arabinose at this rate significantly impaired cerebral metabolism in the ipsilateral hemisphere with minimal or no change in the energy level of the contralateral hemisphere. Infusion of bilirubin further decreased ATP, uridine triphosphate, and guanosine triphosphate levels. To minimize the metabolic effects of barrier disruption, we initially identified the lowest arabinose concentrationlflow rate conditions likely to produce barrier opening. Arabinose (1.5 M) infused at a rate of 0.043 mL.s-' opened the blood-brain barrier in five of seven rats. EEG changes, previously found to coincide with successful barrier opening (24) , were frequently absent under these conditions despite deep Evans blue staining, suggesting that osmolality of the infusate contributes to the EEG change.
Surgical preparation. Nonfasted male Sprague-Dawley rats weighing 280-340 g (mean 3 12 g) were anesthetized with sodium pentobarbital (-50 mg intrapentoneally). Polyethylene catheters (PE50) were placed in the femoral vein for salinelbilirubin infusions and in the femoral artery for blood sampling and blood pressure monitoring. A Portex PElO catheter connected to PESO tubing was then inserted into the right external carotid artery with the tip lying near the carotid bifurcation for saline or arabinose infusion. The pterygopalatine artery, which normally receives about 50% of the internal carotid blood flow, was ligated to assure delivery of the infusate to the brain. The femoral artery catheter was attached to a pressure transducer for measuring blood pressure. The calvarium was exposed and paired cortical screw electrodes were placed over right and left hemispheres with a ground electrode placed over the nose.
Experimental procedure. Before intracarotid infusion, the rat was intubated and placed on a small animal ventilator. Baseline EEG recording, rectal temperature, and BP readings were obtained, and arterial blood gases, pH, and blood glucose were measured. The blood-brain barrier was then opened by infusing 1.5 M l(+)-arabinose (Sigma Chemical Co., St. Louis, MO) through the external carotid artery at a rate of 2.6 mL/min over 30 s (total volume 1.3 mL). Control animals received an equal volume of saline by carotid infusion. Infusates were warmed to 37"C, administered by a constant infusion pump, and filtered inline through a 0.45-~m Millipore filter. One and a half min after the carotid infusion, 3.0 mL bilirubin solution (12-14 mg) or an equal volume of saline was infused through the femoral vein catheter at a rate of 1.0 mL/min for 3 min. Bilirubin (Sigma Chemical Co.) was dissolved in -0.5 mL 0.1 N NaOH and diluted to 3.0 mL with saline, and pH was adjusted to 9.0-9.8 with dilute HCI. The solution was prepared immediately before use and protected from light by wrapping syringe and catheter in aluminum foil. Blood pressure was recorded continuously. Cortical electrical activity over each hemisphere was recorded continuously during intracarotid and i.v. infusions, and intermittently thereafter for 10 min on a Mingograf polygraph (Elema, Stockholm, Sweden). Blood gases, blood glucose, and serum bilirubin were measured at 7 min (2 min after bilirubin infusion) and, in most cases, just before the rats were killed. At 15 min or 4 h, electrodes were removed, and the brain was frozen in situ (25) . The brain was removed by chisel and stored at -80°C until analyzed.
Metabolites were analyzed from -20 mg samples obtained from the right midparietal cortex at least 3 mm lateral from midline. Samples were dissected and extracted with HCI-methano1 at -22°C and subsequently with perchloric acid at O°C, as previously described (26) . Metabolites were measured with enzymatic fluorimetric techniques of Lowry and Passonneau (27) . The adenylate energy charge (E.C.), reflecting the balance between production and utilization of energy (28) , was calculated as:
EEG was interpreted according to degree of amplitude and frequency change using a simple 1 to 3+ scoring system (24) by a neurologist blinded to treatment groups.
Statistical analyses was performed using analysis of variance and Newman-Keuls method for evaluating mean differences. Because of potential variations in barrier opening by arabinose, differences between arabinose and arabinoselbilirubin groups were also analyzed by nonparametric analysis (Mann-Whitney ranking). A value of p < 0.05 was accepted as statistically significant.
RESULTS
The acute effects of intracarotid infusion of saline, arabinose, or arabinose + i.v. bilirubin on brain metabolism are summarized in Table 1 . Energy metabolite levels obtained about 15 min after intracarotid infusion of saline were similar to reported values in pentobarbital anesthetized rats (29) although two out of six saline control animals had slight elevations in lactate and pyruvate. Osmotic opening of the blood-brain barrier acutely decreased PCr (two out of nine) and raised pyruvate and lactate concentrations (three out of nine) in some rats, but group values were not significantly different from values in saline controls. By contrast, infusion of bilirubin to maximum levels of 37-44 mg/ dL (632-752 pmol/L) had a profound immediate effect on energy metabolites in brain. PCr levels at 15 min fell to about 40% of control values and ATP dropped to about 60% of controls, whereas ADP and AMP increased. The calculated adenylate energy charge decreased proportionately. The decrease in high energy metabolites was accompanied by a dramatic drop in brain glucose, brainlblood glucose ratio, and glycogen and an increase in brain lactate. Glucose-6-phosphate and pyruvate decreased slightly in the more severely affected rats, but mean values were similar to saline controls. In arabinose-treated rats, all animals with an elevated lactate had an elevated pyruvate as well. In contrast, four out of five bilirubin-treated rats with high lactate (9-18 Fmol/L) had normal or depressed pyruvate, suggesting that different processes were responsible for the acute metabolic abnormalities induced by barrier opening and bilirubin (Table 2) .
In both arabinose and bilirubinlarabinose groups, energy charge was maintained in the face of dropping brain glucose until very low glucose levels were reached (Fig. I) . High lactate levels persisted even at very low glucose levels, suggesting that bilirubin (and opening of the barrier) resulted in increased glucose utilization in an attempt to sustain energy levels. Increased glucose utilization might occur with either increased energy needs or inhibition of energy production in mitochondria. The high lactate/pyruvate ratio in the bilirubin group (Fig. 2) suggests that the latter problem predominates in the bilirubin-treated animals.
Considerable variation in the severity of response was observed in bilirubin-treated rats ( Table 2 ). The magnitude of metabolic changes had no relationship to the peak bilirubin level achieved. This suggests that differences in metabolic response are most likely due to variations in blood-brain barrier disruption and therefore exposure to bilirubin. Because variations in bamer permeability could skew mean values, differences between arabinose and arabinose/bilirubin groups were also analyzed using a nonparametric test (Mann-Whitney). Significant differences were found with respect to ATP, ADP, AMP, PCr, adenylate energy charge, glucose, glycogen, lactate, and lactate/pyruvate ratio, all with p = 0.0 1 or less (two-tailed).
Baseline blood pressure ranged between 95 and 140 mm Hg. A transient decrease and/or increase in BP was observed in many animals after arabinose infusion. Sustained hypotension (70-90 mm Hg) was seen in two animals, one of which had a marked decrease in PCr. No animal had sustained BP below 40 mm Hg, a threshold previousIy reported to result in altered brain energy metabolism (30) . Blood glucose levels ranged from 6.4 to 11.8 mmol/L. Arterial blood pH ranged from 7.29 to 7.43, and Pcoz ranged from 5.5 to 7.5 kPa. Glucose levels and blood gas values were similar in the different experimental groups and did not correlate with metabolite levels in brain.
In a previous study (24) , using nearly saturated arabinose solutions for carotid infusion, transient alterations in EEG almost invariably accompanied successful opening of the blood-brain barrier. That relationship was not observed in the present study using 1.5 M arabinose, although the most severely affected rats had EEG changes both after arabinose infusion and during bilirubin infusion. EEG abnormalities with 2+ or 3+ changes (primarily a decrease in amplitude) occurred in four out of nine bilirubin-treated and two out of nine arabinose-treated animals. Distinct seizure patterns were not identified.
By 4 h postinfusion, brain and plasma levels of both anesthetics and bilirubin should be negligible (3 l), yet most of the animals remained very lethargic or obtunded. Both arabinose-and bilirubin-treated animals had altered brain metabolism, with increased lactate and decreased nucleotide triphosphates (Table 3 ). All animals tested had normoxemia, but some had a mixed respiratory-metabolic acidosis. In contrast to acute metabolic events, changes in brain ATP and lactate levels in individual rats at 4 h corresponded closely to the magnitude of EEG changes observed during the initial 15-min experimental period (Table  3) . EEG was not recorded at 4 h. Marked elevations in brain lactate were observed in three out of six bilirubin-and two out of five arabinose-treated animals. Histologic studies, performed on an additional four animals killed 4 h after bilirubin infusion demonstrated diffuse neuronal damage and diffuse neuronal histochemical staining for albumin, but no nuclear or cellular staining with bilirubin. Similar, but less severe findings were present in three out of four arabinose controls.
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DISCUSSION
In the presence of a disrupted blood-brain barrier, hyperbilirubinemia induced a pronounced and immediate disturbance of energy metabolism in rat brain including depletion of energy charge, glucose, and glycogen and an increase in lactate and lactate/pyruvate ratio. The lactate/pyruvate ratio depends on the redox state of the cell as well as intracellular pH. The extremely high lactate/pyruvate ratios observed in bilirubin-treated rats cannot be explained by an increase in hydrogen ion concentration alone, indicating a high NADH/NAD+ ratio. This pattern of disturbance is indicative of either severe ischemia or mitochondrial dysfunction involving a block in NADH transport or utilization (32) . Osmotic opening of the blood-brain barrier is accompanied by an initial increase in cerebral blood flow lasting up to 6 min (33), followed by a decrease in flow associated with a mild vasogenic brain edema lasting up to I h (34, 35) . During this time there is uncoupling of cerebral blood flow and metabolism. An increase in glucose uptake and utilization has been reported to accompany osmotic opening of the barrier (34-36), possibly due in part to seizure activity (37) . Brain glucose levels were decreased in only two out of nine arabinose-treated rats in this study, but glucose flux was not measured. The reported decrease in blood flow induced by hypertonic solutions is insufficient to produce ischemia, and bilirubin has no significant effect on cerebral blood flow in the presence of an intact bloodbrain barrier (38) . Possible synergy between bilirubin and hyperosmolar opening of the barrier in decreasing cerebral blood flow, although not specifically excluded in this study, is unlikely. Thus, the observed metabolic effects are most consistent with severe mitochondrial dysfunction.
Mitochondria1 dysfunction is also suggested by the observations of Ives et al., (39) who, using a similar animal model, measured bilirubin-induced changes in brain energy metabolites in rats by 3'P nuclear magnetic resonance spectroscopy. A 35% reduction in PCr/(PCr + inorganic phosphate) ratio occurred at bilirubin levels of 483 + 52 pmol/L (28.3 + 3.0 mg/dL) after hyperosmolar opening of the barrier, but there was no significant change in brain pH. The absence of acidosis precludes a diagnosis of ischemia and supports the conclusion that the elevation of lactate in the presence of a low or normal pyruvate after bilirubin infusion represents intracellular accumulation of NADH.
Although kinetic studies were not performed, metabolite concentrations and ratios found in these rats provide no evidence for inhibition of glycolysis or increased glycogen synthesis as suggested by Katoh-Semba and others (18, 19) using the Gunn rat model. Bilirubin-treated animals with minimal metabolic changes had normal levels of glucose-6-phosphate, pyruvate, and glycogen, with slight elevations in lactate. Moderately affected animals maintained near normal energy levels accompanied by a marked decrease in glucose and rise in lactate and lactate/ pyruvate ratio, and severely affected rats had a marked decrease in brain glycogen and glucose and increased lactate associated with a small decrease in pyruvate. By 4 h postinfusion, glycogen levels returned to near normal values in four of the six bilirubintreated rats, but increased glycogen did not occur. The accumulation of glycogen observed in Gunn rat brains cannot be explained by our findings and may represent a compensatory mechanism in sublethal chronic exposure to bilirubin.
The exact mechanism by which bilirubin produces mitochondrial dysfunction is unknown, and several molecular models describing bilirubin-membrane interaction have been proposed (40) (41) (42) . Under physiologic conditions, tissue binding of bilirubin increases in direct proportion to the hydrogen ion concentration, indicating that it is governed by a single proton addition to bilirubin (43) . Assuming an acid ionization constant for the propionic groups on bilirubin, Wennberg (43) proposed that the proton addition represents conversion of the bilirubin dianion to the monovalent anion. Given suficient fluidity of the mitochondrial membrane, the monoanion might serve as a proton shuttle, altering the tightly controlled hydrogen ion gradient critical for oxidative phosphorylation (4 1). Experimental support for this model is provided by observations that bilirubin increases proton conductance in the inner membrane of rat liver mitochondria (44) and depolarizes mitochondria and plasma membranes in synaptosomes (45). Ostrow et al. (46) recently challenged the assumption that the dianion predominates at physiologic pH, and proposed that the observed partitioning of bilirubin results from formation of the bilirubin acid (by adding a hydrogen ion to the monoanion). Tissue binding of bilirubin would then represent bilirubin acid-lipid complexes that might disturb mitochondrial function by disordering membrane lipid organization. Lipid-protein interactions modulate many transmembrane protein transport systems, e.g. Ca+ ATPase (47) , and are sensitive to changes in lipid-protein environment. A third possible mechanism is specific binding of bilirubin to enzymes involved with mitochondrial function. McLoughlin and Howell (48) found that bilirubin competitively inhibits purified mitochondrial malate dehydrogenase with a rather low ki of 2 pM with respect to NADH binding to the enzyme. Malate dehydrogenase participates in the malate-aspartate shuttle responsible for the transport of reducing equivalents across the inner membrane of the mitochondria. Inhibition of this enzyme would result in the accumulation of NADH in cytoplasm, a high NADH/NAD+ ratio, and secondarily a high lactate/pyruvate ratio as seen in this study.
Osmotic opening of the blood-brain barrier in the absence of hyperbilirubinemia is not innocuous. In this experiment, metabolic sequelae of osmotic opening of the blood-brain barrier appeared to be more severe at 4 h than immediately after the hypertonic arabinose infusion, and there was a striking relationship between brain metabolism at 4 h and acute EEG changes after arabinose infusion. Immediate changes in brain metabolism with opening the blood-brain bamer have been reported to be small (49) , consistent with our findings. Ives et al. (39) reported a greater decrease in brain energy levels from osmotic opening of the blood-brain bamer than we observed, possibly because they used a more hypertonic solution of arabinose (1.8 M). Delayed diffuse neuronal injury after osmotic opening of the blood-brain barrier was observed by Salahuddin et al. (50, 5 I) , who reported changes similar to those observed in our animals. Disruption of the barrier not only exposes brain to an acute hypertonic environment, but abolishes control of brain substrate and protection against potential toxins in serum. Opening the barrier in rats with elevated plasma glutamate levels produced severe delayed neuronal damage, which became apparent only 24-72 h later (52) . Our findings support the proposition that opening the blood brain barrier, even in the absence of bilirubin, may produce brain injury.
Some caution is warranted in extrapolating the results of this study to the pathogenesis of kernicterus in human infants. The population of cortical cells examined in this study might respond differently to a bilirubin load than less mature cells in the traditional target nuclei of newborns. It is also possible that opening the blood-brain bamer creates an environment that alters cellular defense mechanisms leading to a different pattern of response to bilirubin than that seen with an intact blood-brain barrier. The effect of hyperbilirubinemia in the presence of an intact blood-brain barrier was not examined in our model because we considered it unlikely to alter brain. In the presence of an intact blood-brain barrier, short term exposure to very high serum bilirubin concentrations (1063 pmol/L; 62 mg/dL) failed to produce alterations in brain metabolism in the study of Ives et al. (39) and failed to alter electrocortical activity in rats exposed to similar levels for up to 1 h (24) . The importance of the bloodbrain barrier in modulating susceptibility to bilirubin toxicity in newborns is unknown. It is also not known whether early neurologic signs of bilirubin poisoning, e.g. lethargy or altered brainadenylate energy charge stem auditory evoked response, result from impaired energy metabolism or reflect an independent effect of bilirubin on cell function. Our data do not address the mechanism of reversible bilirubin effects in newborn infants, but they do support the proposal that bilirubin can severely inhibit mitochondrial function that may contribute to irreversible bilirubin toxicity.
